BIOMAT Database Logo BIOMAT Database Logo

Therapy with recombinant human insulin-like growth factor I in children with insensitivity to growth hormone and in catabolic conditions. 1993

L E Underwood, and P Backeljauw
Department of Pediatrics, University of North Carolina at Chapel Hill.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008659 Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed) Thesaurismosis,Diseases, Metabolic,Disease, Metabolic,Metabolic Disease,Thesaurismoses
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006130 Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth. Stunted Growth,Stunting,Disorder, Growth,Growth Disorder,Growth, Stunted,Stuntings
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin

Related Publications

L E Underwood, and P Backeljauw
The rationale for the use of recombinant human growth hormone and insulin-like growth factor-I for catabolic conditions in humans.
January 1996, Hormone research,
L E Underwood, and P Backeljauw
Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
September 1992, Acta paediatrica (Oslo, Norway : 1992). Supplement,
L E Underwood, and P Backeljauw
[Therapy with recombinant human insulin-like growth factor I in children with growth hormone receptor insufficiency (Larone's syndrome)].
January 1994, Problemy endokrinologii,
L E Underwood, and P Backeljauw
Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
December 2008, Advances in therapy,
L E Underwood, and P Backeljauw
Adverse events during treatment with recombinant insulin-like growth factor I in patients with growth hormone insensitivity.
April 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement,
L E Underwood, and P Backeljauw
Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity.
April 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement,
L E Underwood, and P Backeljauw
Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
March 2008, Pediatric endocrinology reviews : PER,
L E Underwood, and P Backeljauw
Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
January 2009, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
L E Underwood, and P Backeljauw
Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome.
June 1993, Clinical endocrinology,
L E Underwood, and P Backeljauw
Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.
May 2001, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!